Lymphedema Treatment Market Research Report - Forecast till 2027

Lymphedema Treatment Market Research Report: By Type (Primary Lymphedema, Secondary Lymphedema), By Affected Area (Lower Extremity, Upper Extremity, Genitalia), By Treatment (Compression Devices & Bandaging, Laser Therapy, Drug Therapy & Surgery) and By End-User (Hospitals and clinics, Clinical Research Organizations, Research & Academic Institutes) – Forecast to 2027

ID: MRFR/HC/6968-HCR | February 2021 | Region: Global | 110 pages

Lymphedema Treatment Market Forecast


Lymphedema Treatment Market is estimated to grow with a CAGR of 4.10%.


Market Synopsis


The increasing prevalence of cancer is expected to drive the Lymphedema Treatment Market.


The strong clinical pipeline is likely to boost the market growth. Market players like HERANTIS PHARMA PLC, are developing curative treatment of secondary lymphedema—Lymfactin. Lymfactin is the world’s first and only clinical-stage gene therapy against lymphedema. The market potential of the drug is estimated to be around USD 650 Million.


Market Influencer


Increased research & development in the market is estimated to influence the commercialization in the market. The market is projected to witness a shift from symptomatic treatments to targeted treatment during the forecast period of 2018 to 2025.


Market Drivers



  • Increasing cancer cases


Lymphedema is a medical condition characterized by extra fluid buildup in the body tissues, resulting in a blockage of the lymphatic system.


It is reported that a majority of the lymphedema cases affect cancer patients. The condition can arise immediately after cancer surgery or radiation therapy. However, in certain cases, lymphedema is reported after months or years of cancer treatment. Thus, it is projected that the lymphedema treatment market will grow, parallelly, to the increasing prevalence of cancer.



  • Favorable reimbursement policies

  • Strong pipeline in the market

  • Government support


Market Restraints



  • Limited availability of the treatment options available in the market.

  • Need to change the compression garments at regular intervals.

  • There is a need to change the compression garments at regular intervals. Such garments have a lifespan of approximately six months. This creates reluctance in lymphedema patients to opt for such treatment options, thus, restricting market growth.

  • Late diagnosis of lymphedema


Segmentation


Lymphedema Treatment Market, By Type



  • Primary Lymphedema is caused by the abnormal development of the lymph system. Symptoms may occur at birth or older age. The primary lymphedema segment is estimated to hold the least market share in 2018.

  • Secondary Lymphedema is caused by damage to the lymph system owing to cancer treatment involving surgery, radiation therapy, and others. A majority of the patients suffered from secondary lymphedema making this the leading segment in 2018.


Lymphedema Treatment Market, By Affected Area



  • Lower Extremity: Lower extremity lymphedema involves the swelling of ankles, legs, and feet. This segment is estimated to hold a share of 0% in 2018.

  • Upper Extremity: Upper extremity lymphedema is one of the most poorly understood complications of the disease, making the segment to hold a share of 9.0% in the market in 2018.

  • Genitalia: This segment held the least share of the market in 2018.


Lymphedema Treatment Market, By Treatment



  • Compression Devices & Bandaging: Compression devices are pumps connected to a sleeve that is then wrapped around the affected area that applies pressure. This helps the fluids to circulate through the lymph vessels and veins.

  • Bandaging involves wrapping, thereby helping in preventing the area from refilling with fluid. Lymphedema that has not improved with other treatments can be treated with bandaging. Thus, compression devices & bandaging segment was the largest segment of the lymphedema treatment market in 2018.

  • Laser Therapy: Laser therapy reduces lymphedema swelling after a mastectomy. The segment is estimated to be one of the fastest-growing segments.

  • Drug Therapy & Surgery: Drug therapy and surgery are the least opted treatment in the market, making the segment to hold the least share in the Lymphedema Treatment Market.


Lymphedema Treatment Market, By End-User



  • Hospitals and clinics: By the end, user, hospitals, and clinics holds the largest market share. Favorable government policies and rising awareness campaigns across the globe are responsible for increasing the number of patients seeking treatment through primary healthcare facilities, i.e., hospitals and clinics.

  • Clinical Research Organizations: A growing segment owing to an increasing number of upcoming treatments.

  • Research & Academic Institutes: Rapid technological advances and research & development collaborations are leading to significant growth by this segment.


Lymphedema Treatment Market,By Region



  • Americas: The Americas is the largest regional market owing to the increasing prevalence of cancer and the presence of major market players such as Tactile Medical, in the region. In 2018, around 1,735,350 cases of cancer were diagnosed in the US.

  • Europe: Europe accounted for the second-largest market share in 2018. Rising healthcare expenditure and the presence of developed economies drive the European regional market for lymphedema treatment. It was reported that ~USD 5,490.1 was the per capita healthcare expenditure in Europe in 2016.

  • Asia-Pacific: The fastest-growing regional market for lymphedema treatment. Asia-Pacific has the world’s largest population, and fast-developing healthcare industry whiten countries including China and India.

  • Middle East & Africa: Underdeveloped healthcare infrastructure in the region makes it very difficult for the manufactures to reach their consumers. Moreover, the presence of stringent government regulations restraints Lymphedema Treatment Market growth.


Key Players



  • 3A Health Care (Italy)

  • Bio Compression Systems, Inc. (US)

  • Devon Medical Products (US)

  • HERANTIS PHARMA PLC (Finland)

  • Lohmann & Rauscher (Germany)

  • Mego Afek Ltd (US)

  • SIGVARIS (Switzerland)

  • Tactile Systems Technology Inc. (US)

  • Wright Therapy Products (BSN Medical) (Germany)



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2019-2025:4.10%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Affected Area, Treatment and End-User
  Geographies Covered    North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   3A Health Care (Italy), Bio Compression Systems, Inc. (US), Devon Medical Products (US), HERANTIS PHARMA PLC (Finland), Lohmann & Rauscher (Germany), Mego Afek Ltd (US), SIGVARIS (Switzerland), Tactile Systems Technology Inc. (US), Wright Therapy Products (BSN Medical) (Germany)
  Key Market Opportunities   Increased research & development in the market is estimated to influence the commercialization in the market
  Key Market Drivers

  • Increasing cancer cases
  • Favorable reimbursement policies
  • Favorable reimbursement policies
  • Strong pipeline in the market
  • Government support


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    lymphedema treatment market is projected grow at approximately 4% CAGR during the assessment period (2019-2025).

    The valuation of the global lymphedema treatment market is estimated to increase to USD 650 MN by the end of 2025.

    Favorable reimbursement policies, Strong pipeline in the market, and Government support are the major tailwinds pushing the growth of the global lymphedema treatment market.

    North America holds the largest share in the global lymphedema treatment market, followed by Europe and the Asia Pacific, respectively.

    3A Health Care (Italy), Bio Compression Systems, Inc. (US), Devon Medical Products (US), Herantis Pharma Plc (Finland), Lohmann & Rauscher (Germany), Mego Afek Ltd (US), SIGVARIS (Switzerland), Tactile Systems Technology Inc. (US), and Wright Therapy Products (Germany), are some of the major players operating in the global lymphedema treatment market.



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.